⚲
|
Vertex Pharmaceuticals Inc / Ma | |
---|---|
Ticker | VRTX |
CIK # | 0000875320 |
CUSIP | 92532F100 |
Sector | Life Sciences |
Industry | Pharmaceutical Preparations |
Phone | 6165776000 |
Address | 130 Waverly Street Cambridge, MA 02139-4242 |
Source | [EDGAR] |
Market Cap, 13F ($) |
---|
Business |
---|
We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. Our goal is to develop treatment regimens that will provide benefits to all patients with cystic fibrosis, or CF, and will enhance the benefits that currently are being provided to patients taking our medicines. Our marketed medicines are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). We obtained approval from the U.S. Food and Drug Administration, or the FDA, for TRIKAFTA, our triple combination regimen, in October 2019. This approval increased the number of patients eligible for our medicines in the U.S. by approximately 6,000 and provided an additional treatment option for many patients who are also eligible for one of our previously approved products. We have submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, for this triple combination regimen. The FDA approval and the MAA filing were based on positive data from Phase 3 clinical trials evaluating the triple combination regimen in patients 12 years of age or older (i) who have a copy of the F508del mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene and a second mutation that results in minimal CFTR function, whom we refer to as F508del/Min patients, and (ii) who have two copies of the F508del mutation, whom we refer to as F508del homozygous patients. Our four medicines are collectively approved to treat approximately 60% of the 75,000 CF patients in North America, Europe and Australia. We are focused on obtaining approval for the triple combination in ex-U.S. markets for patients 12 years of age and older and evaluating our triple combination in younger patients, with the goal of having treatments for up to 90% of patients with CF. We are also pursuing other therapeutic approaches to address the remaining 10% of CF patients. Our goal is to identify and develop new medicines by combining transformative advances in the understanding of human disease and in the science of therapeutics to advance human health. |
CIK | Filing | 2011 - 2023 |
---|---|---|
[0000875320] | 10-K | |
[0000875320] | 10-Q | |
[0000875320] | 3 | |
[0000875320] | 4 | |
[0000875320] | 5 | |
[0000875320] | 8-K | |
[0000875320] | SC 13D | |
[0000875320] | SC 13G |